Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$64.06
-1.9%
$45.23
$30.04
$71.13
$5.52B1.822.02 million shs2.41 million shs
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$12.83
+13.3%
$8.94
$5.00
$16.85
$754.57M1.481.44 million shs2.40 million shs
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$151.83
+2.5%
$136.57
$122.80
$219.34
$4.38B0.67285,771 shs64,329 shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$38.22
-0.5%
$39.11
$29.17
$62.40
$7.12B1.061.62 million shs481,622 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
+0.31%+15.79%+47.64%+66.53%+19.74%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
+11.60%+14.03%+32.49%+50.23%-15.46%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
+0.41%-1.54%+11.80%-12.27%-27.29%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
+0.31%+0.13%-3.13%+4.23%-16.73%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2.8486 of 5 stars
3.31.00.00.03.83.30.6
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
0.6878 of 5 stars
1.01.00.00.02.52.50.6
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
4.5305 of 5 stars
3.51.00.04.72.23.31.9
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
4.5498 of 5 stars
4.53.00.04.72.71.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2.53
Moderate Buy$71.7512.00% Upside
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
2.00
Hold$8.50-33.73% Downside
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
3.00
Buy$213.7540.79% Upside
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
3.00
Buy$68.9180.30% Upside

Current Analyst Ratings Breakdown

Latest DNA, CRSP, KRYS, and RVMD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/15/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$65.00
7/9/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$155.00 ➝ $176.00
7/8/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$81.00
6/27/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$105.00
6/27/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$86.00
6/27/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$65.00
6/26/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$81.00
6/26/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$82.00
6/25/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00
6/24/2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$240.00
6/24/2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$67.00 ➝ $73.00
(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$35M158.07N/AN/A$22.64 per share2.83
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
$227.04M3.31N/AN/A$13.17 per share0.97
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$333.45M13.16$4.77 per share31.81$32.90 per share4.61
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$11.58M614.79N/AN/A$13.47 per share2.84
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$366.25M-$4.52N/AN/AN/A-1,023.64%-20.08%-17.13%8/4/2025 (Estimated)
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$547.03M-$9.16N/AN/AN/A-198.84%-52.35%-27.14%8/14/2025 (Estimated)
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$89.16M$4.1636.4415.06N/A37.17%14.64%13.28%8/4/2025 (Estimated)
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$600.09M-$4.00N/AN/AN/AN/A-37.06%-32.84%8/6/2025 (Estimated)

Latest DNA, CRSP, KRYS, and RVMD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$1.44N/AN/AN/AN/AN/A
8/6/2025Q2 2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.14N/AN/AN/A$0.50 millionN/A
8/4/2025Q2 2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$1.54N/AN/AN/A$6.44 millionN/A
8/4/2025Q2 2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$1.20N/AN/AN/A$95.42 millionN/A
5/7/2025Q1 2025
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.12-$1.13-$0.01-$1.13N/AN/A
5/6/2025Q1 2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$1.27-$1.58-$0.31-$1.58N/AN/A
5/6/2025Q1 2025
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
-$1.23-$1.58-$0.35-$1.68$38.70 million$48.32 million
5/6/2025Q1 2025
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$1.38$1.20-$0.18$1.20$98.66 million$88.18 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/AN/AN/AN/AN/A
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
N/AN/AN/AN/AN/A
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/AN/AN/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/A
15.64
15.64
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
N/A
4.88
4.88
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/A
9.65
9.27
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/A
13.46
13.46

Institutional Ownership

CompanyInstitutional Ownership
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
69.20%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
78.63%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
86.29%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
94.34%

Insider Ownership

CompanyInsider Ownership
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
4.30%
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
9.72%
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
13.70%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
8.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
46086.36 million82.82 millionOptionable
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
64058.53 million52.84 millionOptionable
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
21028.90 million24.94 millionOptionable
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
250186.27 million170.99 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRISPR Therapeutics stock logo

CRISPR Therapeutics NASDAQ:CRSP

$64.06 -1.27 (-1.94%)
As of 01:10 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Ginkgo Bioworks stock logo

Ginkgo Bioworks NYSE:DNA

$12.83 +1.51 (+13.31%)
As of 01:10 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Krystal Biotech stock logo

Krystal Biotech NASDAQ:KRYS

$151.82 +3.74 (+2.52%)
As of 01:09 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Revolution Medicines stock logo

Revolution Medicines NASDAQ:RVMD

$38.22 -0.20 (-0.52%)
As of 01:10 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.